Literature DB >> 27865805

Transcriptional activation by MLL fusion proteins in leukemogenesis.

Akihiko Yokoyama1.   

Abstract

Chromosomal translocations involving the mixed lineage leukemia (MLL) gene cause aggressive leukemia. Fusion proteins of MLL and a component of the AF4 family/ENL family/P-TEFb complex (AEP) are responsible for two-thirds of MLL-associated leukemia cases. MLL-AEP fusion proteins trigger aberrant self-renewal of hematopoietic progenitors by constitutively activating self-renewal-related genes. MLL-AEP fusion proteins activate transcription initiation by loading the TATA-binding protein (TBP) to the TATA element via selectivity factor 1. Although AEP retains transcription elongation and mediator recruiting activities, the rate-limiting step activated by MLL-AEP fusion proteins appears to be the TBP-loading step. This is contrary to prevailing views, in which the recruitment of transcription elongation activities are emphasized. Here, I review recent advances towards elucidating the mechanisms underlying gene activation by MLL-AEP fusion proteins in leukemogenesis.
Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27865805     DOI: 10.1016/j.exphem.2016.10.014

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  14 in total

1.  [Clinical features and prognosis of children with acute lymphoblastic leukemia and different platelet levels].

Authors:  Ao-Li Zhang; Xiao-Juan Chen; Yao Zou; Wen-Yu Yang; Ye Guo; Shu-Chun Wang; Li Zhang; Xiao-Ming Liu; Min Ruan; Tian-Feng Liu; Ben-Quan Qi; Xiao-Fan Zhu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

2.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

Authors:  Michael R McKeown; M Ryan Corces; Matthew L Eaton; Chris Fiore; Emily Lee; Jeremy T Lopez; Mei Wei Chen; Darren Smith; Steven M Chan; Julie L Koenig; Kathryn Austgen; Matthew G Guenther; David A Orlando; Jakob Lovén; Christian C Fritz; Ravindra Majeti
Journal:  Cancer Discov       Date:  2017-07-20       Impact factor: 39.397

3.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

Review 4.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

5.  Peptidomimetics for Targeting Protein-Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL.

Authors:  Lei Du; Sierrah M Grigsby; Aihong Yao; Yujie Chang; Garrett Johnson; Haiying Sun; Zaneta Nikolovska-Coleska
Journal:  ACS Med Chem Lett       Date:  2018-08-06       Impact factor: 4.345

6.  Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates HOXA9 Gene Expression in t(4;11) Leukemia Cells.

Authors:  Tiziana Fioretti; Armando Cevenini; Mariateresa Zanobio; Maddalena Raia; Daniela Sarnataro; Fabio Cattaneo; Rosario Ammendola; Gabriella Esposito
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

7.  Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia.

Authors:  James N Fisher; Angeliki Thanasopoulou; Sabine Juge; Alexandar Tzankov; Frederik O Bagger; Max A Mendez; Antoine H F M Peters; Juerg Schwaller
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

Review 8.  RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation.

Authors:  Akihiko Yokoyama
Journal:  Front Genet       Date:  2019-01-14       Impact factor: 4.599

9.  Molecular characterization of an MLL1 fusion and its role in chromosomal instability.

Authors:  Sreejit Parameswaran; Frederick S Vizeacoumar; Kalpana Kalyanasundaram Bhanumathy; Fujun Qin; Md Fahmid Islam; Behzad M Toosi; Chelsea E Cunningham; Darrell D Mousseau; Maruti C Uppalapati; Peter C Stirling; Yuliang Wu; Keith Bonham; Andrew Freywald; Hui Li; Franco J Vizeacoumar
Journal:  Mol Oncol       Date:  2018-12-31       Impact factor: 6.603

10.  TXNIP induces growth arrest and enhances ABT263-induced apoptosis in mixed-lineage leukemia-rearranged acute myeloid leukemia cells.

Authors:  Mina Noura; Hidemasa Matsuo; Asami Koyama; Souichi Adachi; Hiroshi Masutani
Journal:  FEBS Open Bio       Date:  2020-06-24       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.